Language
Germany

Closure notice · 13.10.2026

Supply shortage Germany: Actos 15 mg Tabletten - OP112

Affected country: Germany · Reported period: 30.06.2026 – 07.10.2026 · Active ingredient: Pioglitazonhydrochlorid

Illustration of medicine supply and shortage monitoring in Europe – Supply shortage Actos 15 mg Tabletten - OP112 | PZN 06430701
Illustration of medicine supply and shortage monitoring in Europe – Supply shortage Actos 15 mg Tabletten - OP112 | PZN 06430701
CountryGermany
PZN06430701
ENRLE2026003764
Notification typeClosure notice
Start30.06.2026
Expected end07.10.2026
Last update13.10.2026
ReasonProduction problem
ATCA10BG03
Hospital-relevantNo

Notice context

A supply shortage has been recorded for Actos 15 mg Tabletten - OP112 in Germany. The stated reason is “Production problem”. The notice concerns the active ingredient Pioglitazonhydrochlorid and is not identified as hospital-relevant.

This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.

Primary source: PharmNet.Bund / BfArM

Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.

Check the official notice list →

Implications for procurement and the supply chain

The notice for Actos 15 mg Tabletten - OP112 is a supply signal concerning Pioglitazonhydrochlorid in Germany. The published reason “Production problem” determines which data should be verified first.

For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.

Decision route for this supply case

  1. Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
  2. Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
  3. Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.

Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.

Request a structured supply review →

Operational shortage resilience: GDP warehousing and pharmaceutical storage

For manufacturing shortages, an agreed restart stock for Actos 15 mg Tabletten - OP112 can be received and distributed under control after release.

Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.

Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.

Operational checks for this notice

  • Match product identity using PZN 06430701, active ingredient, strength, dosage form and pack.
  • Confirm the reported status and the period 30.06.2026 to 07.10.2026 with the primary source and potential suppliers.
  • Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
  • Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.

Relevant services and specialist pages

The following B2B topics are particularly relevant when handling a shortage involving Actos 15 mg Tabletten - OP112:

Related topics